Feasibility of Using an App for Managing Phantom Limb Pain Associated with Combat Injury in Ukraine (PAMELA)
Launched by WINFRIED MEISSNER · Sep 17, 2024
Trial Information
Current as of July 01, 2025
Not yet recruiting
Keywords
ClinConnect Summary
The PAMELA trial is studying the use of a special app designed to help people who have lost a limb due to injuries from the war in Ukraine manage their phantom limb pain. Phantom limb pain is a common issue for amputees, where they still feel pain in the limb that is no longer there. The app offers different techniques that do not involve medication, focusing on helping individuals cope with their pain in a supportive and accessible way. The trial will take place in two phases, starting with a pilot program at five rehabilitation centers to see how well the app works for a group of amputees over eight weeks, followed by an additional four weeks where they can use the app on their own.
To participate in this study, individuals must be adults who have had an amputation of one limb and can provide written consent to join. The trial is open to all genders and aims to gather important feedback to make the app even better for future users. It's a great opportunity for amputees in Ukraine to explore new ways to manage their pain and improve their quality of life, especially in a time when access to traditional care may be limited.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Amputee has given written informed consent for participation in the study.
- • Male or Female
- • Age - no restriction but adult
- • Have undergone amputation of one limb, upper or lower.
- Exclusion Criteria:
- • For Graded Motor Imagery / Mirror therapy Amputees with disorders such as post-traumatic stress disorders should perform mirror therapy only after initial assessment by the therapist carrying out the treatment, as the mirror image of two intact limbs might elicit memories associated with the trauma
About Winfried Meißner
Winfried Meißner is a distinguished clinical trial sponsor known for his commitment to advancing medical research and improving patient outcomes. With a robust background in clinical pharmacology and extensive experience in managing clinical studies, he focuses on innovative therapeutic solutions across various therapeutic areas. His organization emphasizes rigorous study design, ethical standards, and collaboration with healthcare professionals to ensure the integrity and reliability of clinical data. Dedicated to fostering advancements in healthcare, Winfried Meißner is a respected leader in the clinical research community, driving initiatives that contribute to the development of safe and effective treatments.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Kharkiv, , Ukraine
Kyiv, , Ukraine
Odesa, , Ukraine
Vinnytsia, , Ukraine
Vinnytsia, , Ukraine
Patients applied
Trial Officials
Winfried Meissner, MD
Principal Investigator
Jena University Hospital
Volodymyr Romanenko, MD
Principal Investigator
Vita Medical
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported